

UNITED STATES CONTINUING UTILITY PATENT APPLICATION  
under 37 C.F.R. § 1.53(b)

Page 1

Atty. Docket No. 01107.76459

RECEIVED

Assistant Commissioner of Patents  
Box Patent Applications  
Washington, D.C. 20231

JAN 19 1999

U.S. PATENT AND TRADEMARK OFFICE  
SERVICE CENTER

Enclosed herewith is a continuing patent application and the following papers:

First Named Inventor (or application identifier): David Sidransky

Title of Invention: DETECTION OF HYPERMUTABLE NUCLEIC ACID SEQUENCE IN TISSUE

- Continuation
- Divisional
- Continuation-in-Part

of prior application No. 08/854,727, filed May 12, 1997

1.  Specification 61 pages (including specification, claims, abstract) / 22 claims (2 independent)
2.  Declaration/Power of Attorney:
  - Copy from Prior Application (for continuation or divisional application)
  - Newly Executed Declaration (for CIP application)
  - Deferred under 37 C.F.R. § 1.53(f)
  - Deletion of Inventor(s) - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b)
  - Incorporation by Reference - The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein
3.  4 Distinct sheets of  Formal  Informal Drawings
4.  Preliminary Amendment
5.  Information Disclosure Statement
  - Form 1449
  - A copy of each cited prior art reference
6.  Assignment
  - Assignment with Cover Sheet attached
  - Assignment filed in prior application. Application assigned to: The Johns Hopkins University
7.  Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

**UNITED STATES CONTINUING UTILITY PATENT APPLICATION**  
 under 37 C.F.R. § 1.53(b)

Page 2

Atty. Docket No. 01107.76459

Country	Application Number	Date of Filing (day, month, year)

8.  Priority document(s)
9.  Small Entity Statement
  - Small Entity Statement was filed in prior application, Small Entity Status is still proper and desired
  - is attached
  - is no longer claimed
10.  Microfiche Computer Program (Appendix)
11.  Nucleotide and/or Amino Acid Sequence Submission
  - Computer Readable Copy
  - Paper Copy (identical to computer copy)
  - Statement verifying identity of above copies
12. Calculation of Fees:

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			\$790.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	2	22.00	\$44.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	0	82.00	\$0.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	0	270.00	\$0.00
Subtotal - Filing Fee Due			\$834.00
		MULTIPLY BY	
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0.50		\$417.00
<b>TOTAL FILING FEE DUE</b>			<b>\$417.00</b>
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
<b>GRAND TOTAL DUE</b>			<b>\$417.00</b>

13. PAYMENT is:
- included in the amount of the GRAND TOTAL by our enclosed check. A general authorization under 37 C.F.R. § 1.25(b), second sentence, is hereby given to credit or debit our Deposit Account No. 19-0733 for the instant filing and for any other fees during the pendency of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18
  - not included, but deferred under 37 C.F.R. § 1.53(f).

**UNITED STATES CONTINUING UTILITY PATENT APPLICATION**  
under 37 C.F.R. § 1.53(b)

Page 3

Atty. Docket No. 01107.76459

14. All correspondence for the attached application should be directed to:

Banner & Witcoff, Ltd.  
1001 G Street, N.W.  
Washington, D.C. 20001-4597  
Telephone: (202) 508-9100  
Facsimile: (202) 508-9299

15. Other: \_\_\_\_\_

Date: October 1, 1998

By: Sarah A. Kagan  
Sarah A. Kagan  
Reg. No. 32,141

SAK/ama